home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

7th Protein Kinases in Drug Discovery

 
  February 03, 2012  
     
 
GTC Company, Global Technology Community 434 W. Foothill Blvd Monrovia, CA 91016
2012-05-30


Despite the hundreds of kinase inhibitors currently in discovery and pre-clinical phases, the number of kinase inhibitors which have been approved and are on the market remains low by comparison. This discrepancy reflects the challenges which accompany the development of ATP-competitive kinase inhibitors, including low specificity and off-target binding. There is also the problem of gatekeeper-associated drug resistance. To remain competitive in the kinase field, it will require you to stay abreast with recent development trends and technological advancements aimed at circumventing these issues. We will also provide you with a broad overview of the role kinases play in various types of cancer as well as introduce you to several novel kinases and inhibitor candidates.
 
 
Organized by: GTC
Invited Speakers:
Alex Bullock, Ph.D.
Principal Investigator 
SGC, University of Oxford
 
Thomas Chan
ArQule
 
Xianming Deng, Ph.D. 
Principal Investigator
School of life sciences, Xiamen University
 
Thomas A. Engler, Ph.D.
Senior Research Advisor, Discovery Chemistry Research and Technologies 
Eli Lilly
 
Nathanael Gray, Ph.D.
Associate Professor, Department of Biological Chemistry and Molecular Pharmacology
Harvard Medical School
Cancer Biology
Dana-Farber Cancer Institute
 
Richard Lewis, Ph.D.
Principal Scientist
Amgen
 
Min Liu, Ph.D.
Instructor in Neurology, Neurology
Brigham and Women's Hospital
 
Matthew Lucas
Senior Scientist
Hoffmann La Roche
 
Jeffrey R Peterson, Ph.D.
Associate Professor
Fox Chase Cancer Center
 
Leo Price, Ph.D.
Leiden Amsterdam Center for Drug Research
 
Gary L. Schieven, Ph.D.
Research Fellow, Immunology Drug Discovery
Bristol-Myers Squibb
 
Markus Seeliger
Assistant Professor, Pharmacological Sciences
Stony Brook University Medical School
 
Juswinder Singh, Ph.D.
Co-Founder & Chief Scientific Officer
Avila Therapeutics
 
Matthew Soellner, Ph.D.
Assistant Professor, Medicinal Chemistry
University of Michigan
 
Michael B Yaffe , M.D., Ph.D.
David H. Koch Professor, Koch Institute for Integrative Cancer Research, 
Depts of Biology and Biological Engineering and Division of Health Sciences and Technology; 
Senior Associate Member, Broad Institute
Massachusetts Institute of Technology
 
Deadline for Abstracts: 2012-05-31
 
Registration: GTCbio is proud to present our 7th Protein Kinases in Drug Discovery Conference! This meeting will be held May 30-31, 2012 at the Hyatt Harbor Hotel in historical Boston, Massachusetts, one of the most concentrated academic and industrial areas in the United States. We will bring together industry leaders from major pharmaceutical companies, biotech companies as well as top researchers from academia and government to provide you with a better understanding of the complex activities of kinases and some solutions to the challenges associated with kinase drug development. The meeting will offer you an intimate forum to engage in discourse with other distinguished researchers involved in the most cutting-edge kinase work!
E-mail: ken.lin@gtcbio.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.